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Background:  Vaccines  are  speciﬁc  medicines  characterized  by  two  country-speciﬁc  market  access  pro-
cesses:  (1)  a recommendation  by  National  Immunization  Technical  Advisory  Group  (NITAG),  and  (2)  a
funding  policy  decision.
Objectives:  The  objective  of  this  study  was  to compare  and  analyze  NITAGs  of 13 developed  countries  by
describing  vaccination  committees’  bodies  and  working  processes.
Methods:  Information  about  NITAGs  bodies  and  working  processes  was  searched  from  ofﬁcial  sources
from  June  2011 to November  2012.  Retrieved  information  was  completed  from  relevant  articles  identiﬁed
through  a  systematic  literature  review  and by  information  provided  by  direct  contact  with  NITAGs  or
parent organizations.  An expert  panel  was  also  conducted  to  discuss,  validate,  and  provide  additional
input  on  obtained  results.
Results:  While  complete  information,  deﬁned  as 100%,  was  retrieved  only  for  the  UK,  at least  80%  of  data
was retrieved  for 9  countries  out  of  the  13  selected  countries.  Terms  of  references  were  identiﬁed  in  7
countries,  and the main  mission  for all NITAGs  was  to provide  advice  for National  immunization  programs.
However,  these  terms  of  references  did  not fully  encompass  all  the  actual  missions  of  the  NITAGs.  Decision
analysis  frameworks  were  identiﬁed  for  10 out of the 13, and  all  NITAGs  considered  at least  four  criteria
for decision-making:  disease  burden,  efﬁcacy/effectiveness,  safety  and  cost-effectiveness.  Advices  were
published  by most  NITAGs,  but  few  NITAGs  published  meeting  agendas  and  minutes.  Only  the  United
States  had open  meetings.
Conclusions:  This  study  supports  previous  ﬁndings  about  the  disparities  in NITAGs  processes  which  could
potentially  explain  the  disparity  in  access  to vaccinations  and  immunization  programs  across  Europe.
With  NITAGs  recommendations  being  used  by policy  decision  makers  for implementation  and  funding  of
vaccine  programs,  guidances  should  be well-informed  and  transparent  to  ensure  National  Immunization
Programs’  (NIP) credibility  among  the  public  and  health  care  professionals.
ublis© 2014  The  Authors.  P
. IntroductionVaccines follow country-speciﬁc market access paths that
iffer from traditional registration processes. Vaccines’ market
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
access processes are characterized ﬁrst by the development of
recommendations, and are followed by the executive policy-
decision, which includes funding and which is usually based on
the recommendations.Expert committees, referred as National Immunization Tech-
nical Advisory Group (NITAG), are in charge of developing
recommendations that are ultimately used by policy-makers to
make evidence-based decisions on immunization-related policies
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
List of data searched for each NITAG.
List of 25 relevant items searched for each selected country’s NITAG
Name of the NITAG
NITAG’s website/ofﬁcial source
Role/missions of NITAG stated on the website/ofﬁcial source
Name of NITAG’s parent organization
Identiﬁcation of the stakeholders (non-core members) involved in NITAG’s
meetings
Role of the stakeholders involved during the meetings
Number of NITAG’s core members
Name of NITAG’s core members
Proﬁle composition of NITAG’s core members
Are the core members full time employees of the NITAG?
Selection process of chairman/other core members
Duration of appointment for core members
Are the core members remunerated?
Do core members declare conﬂicts of interest?
Number of NITAG’s meetings per year
Length of NITAG’s meetings
Do subcommittees exist within the NITAG?
Are NITAG’s meetings open to public?
Are the NITAG’s meeting agendas published before the meetings?
Are  the NITAG’s meeting minutes published after the meetings?
Are the NITAG’s recommendations published after the meetings?
Are  the NITAG’s recommendations published through evaluation reports?
What is the timeline to get the NITAG’s recommendations publicly
available? G.W. Ricciardi et al.
nd programs, such as the inclusion of the new vaccine in the
ational immunization program (NIP) [1].
NITAGS are country- speciﬁc, thus varying greatly from one
ountry to another. Indeed, Lopalco et al. concluded in their
tudy that NITAGs’ policy, including analysis framework and deci-
ions processes, were heterogeneous across European Union (EU)
ember states [2]. Piso et al. performed a Delphi panel of 14
mmunization experts and drew similar conclusions about the
eterogeneity of decision-making criteria and processes within
uropean NITAGs [3].
Immunization policy development processes were also stud-
ed Bryson et al. who presented the results of a global survey
erformed in 2008 with the World Health Organization (WHO)
4]. Duclos et al. performed an update of the same global survey,
eporting impressive progress in NITAGs establishment and per-
ormance and proposing general guidelines for the NITAGs [5,6].
ore recently, a collaborative project, Vaccine European New Inte-
rated Collaboration Effort II (VENICE II), involving 29 EU countries,
as implemented to collect and share information on immuniza-
ion programs through a network of professionals to improve the
verall performance of the immunization systems [7].
While Duclos and Piso’s work provided valuable input on
ITAGs processes, there is still need for up-to-date informa-
ion about NITAGs’ policies and recommendations in developed
ountries. Indeed, understanding vaccination recommendation
rocesses is crucial for health policy decision makers, public
ealth specialists, and civil society. Furthermore, a comparison
etween several NITAGs would allow the identiﬁcation of both
ood practices and shortcomings, and thus pinpoint areas in need of
mprovement. Therefore, the objective of this study was to compare
nd analyze NITAGs of a selected number of developed countries by
escribing vaccination committees’ bodies and working processes.
he comparison aimed to cover all aspects of NITAGs’ policy such as
eporting, terms of reference, composition, meeting organization,
ecision analysis framework, and communication.
. Methodology
The study was conducted from June 2011 to November 2012
n 13 countries: Australia, Belgium, Canada, France, Germany,
ungary, Italy, the Netherlands, Spain, Sweden, Switzerland, the
nited Kingdom (UK) and the United States (US). Speciﬁc European
ountries were selected to provide a reasonable representation of
eveloped countries and to reﬂect a variety of health care organi-
ations and funding mechanisms. Three non-European countries,
ustralia, Canada, and the US, were selected because of their long
istory of NITAG practice and the quality and transparency of their
ecision processes [4,6].
.1. Data extraction
Twenty-ﬁve relevant items, based on Duclos et al. work, were
elected to compare NITAGs’ processes in the selected countries.
iso et al. article was used to establish a list of relevant criteria
sed for analytical framework) [6,8] (Table 1). Data was extracted
rom the following three types of sources:
 Source 1: Ofﬁcial sources deﬁned as NITAGs’ websites, or when
unavailable, those of the relevant parent organizations plus
NITAG resource center [9].
 Source 2: Articles identiﬁed through a systematic literature
review that was performed using the same search strategy
and databases (OVID Medline and Global Health) as Bryson
et al. [4] (Appendix 1). An additional, ad-hoc search was  also
performed for relevant article on the International Society forDo  the NITAG possess analytical frameworks for decision-making?
Criteria used for analytical framework
Pharmacoeconomics and Outcomes Research abstracts database
and Google scholar.
- Source 3: Direct contact (primary research) with the NITAGs or
their parent organizations via interviews or questionnaires.
Data were searched through hierarchically ordered sources
(source 1, then 2 and last 3). The same information found in several
sources was reported as retrieved from the ﬁrst source.
2.2. Data validation and review by the immunization expert panel
Retrieved information was reviewed by an international immu-
nization expert panel composed of 8 members from France,
Germany, Hungary, Italy, Spain, the UK and the US. All experts
were familiar with vaccine evaluation and NITAGs. There were four
experts were current or former members of NITAGs, two public
health specialists, two health economists, among which a patients’
representative from European Patients Forum. The immunization
expert panel was convened for a one-day meeting and provided
complementary information and clariﬁcations in order to validate
the overall study ﬁndings and provided context and details sur-
rounding various NITAG’s processes.
2.3. Analysis
Retrieved information analysis was  performed using usual
descriptive statistics, i.e. proportions (Table 2).
3. Results
3.1. Source identiﬁcation and data collection
Via ofﬁcial sources (Source 1), NITAGs’ websites or parent orga-
nization websites were identiﬁed for all selected countries except
Italy [10–21] (Table 2).
A total of 1658 articles were identiﬁed through the litera-
ture review, and 281 duplicates and 1352 articles were excluded
through titles and abstracts review. Thus, 25 studies meeting the
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Table 2
Overview of NITAG’s ofﬁcial sources and of the proportion of information retrieved by source.
Name of NITAG Ofﬁcial Sources*,+ Proportion of data retrieved by source
Secondary Research Primary Research Not found
Source 1‡ Source 2‡ Source 3‡
European Countries
Belgium Standing Working Group on Vaccination (Groupe de
travail permanent Vaccination-Permanente werkgroep
Vaccinatie)
www.health.belgium.be 40% 4% 40% 16%
France  Technical Vaccination Committee (Comité technique des
vaccinations;  CTV)
www.hcsp.fr 46% – 46% 8%
Germany The German Standing Vaccination Committee (Ständigen
Impfkommission; STIKO)
www.rki.de 96% – – 4%
Hungary National Center for Epidemiology Committee (Országos
Epidemiológiai Központ; OEK)
www.oek.hu 8% 4% 56% 32%
Italy  National Vaccines Commission (Nazionale Vaccini
Commissione; CNV)
Not found¥ 16% 4% 80%
The  Netherlands Committee on the National Vaccination Program
(Commissie Rijksvaccinatieprogramma; RVP)
www.gezondheidsraad.nl 32% 4% 52% 12%
Spain  Working Group on Vaccines (Ponencia del Programa y
Registro de Vacunaciones i.e. Ponencia de Vacunas)
www.msps.es 44% 4% – 52%
Sweden  National Board of Health and Welfare Expert
Committees (SocialStyrelsen)
www.socialstyrelsen.se 16% 8% 56% 20%
Switzerland The Federal Vaccination Commission (Commission
fédérale pour les vaccinations – Commissione federale per
le  vaccinazioni – Eidgenössische Kommission für
Impffragen; CFV)
www.bag.admin.ch 44% 44% – 12%
UK  The Joint Committee on Vaccination and Immunization
(JCVI)
www.gov.uk/government/organisations/department-of-health 100% – – 0%
Non-European countries
Australia Australian Technical Advisory Group on Immunization
(ATAGI)
www.health.gov.au 40% 36% – 24%
Canada  The National Advisory Committee on Immunization
(NACI)
www.phac-aspc.gc.ca/naci-ccni 32% 52% – 16%
US¤ The Advisory Committee on Immunization Practices
(ACIP)
www.cdc.gov 96% – – 4%
* Websites of NITAGs, or, when not available, those of the relevant parent organization.
+ Other Source: NITAG Resource Center [9].
‡ Source 1: Websites of NITAGs or the relevant parent organization; Source 2: systematic literature review; Source 3: direct contact (primary research) with the NITAGs or their parent organizations.
¥ No ofﬁcial website, however the National Plan of Vaccination (Nazionale Prevenzione Vaccinale) 2012–2014 was  available [33].
§ The National Board of Health and Welfare does not have a standing vaccine committee, as such ‘Vaccine committees’ are founded on an ad-hoc basis, as per primary research.
¤ Smith et al article “The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP)” (Vaccine 2010; [30]) was available on CDC’s website, thus considered as source 1.
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nclusion criteria were used as a secondary source to supplement
he information retrieved through ofﬁcial websites.
Finally, primary research information was obtained for Belgium,
ungary, the Netherlands and Sweden to complete information not
vailable from Sources 1 and 2.
.2. Overview of retrieved information
Complete information, deﬁned as 100% (i.e. 25 items retrieved
n 25), was retrieved only for the UK. The proportion of unfound
ata ranged from 0% in UK to 80% in Italy, and the level of retrieved
nformation through the ofﬁcial sources was below 50% for 10 coun-
ries (Table 2).
.3. NITAGs’ mandate and actual missions
Terms of reference, deﬁning the ofﬁcial mandate of the NITAG,
ere retrieved for a narrow majority of countries (7 countries
ut of 13; Table 3). Terms of reference were stated in ofﬁcial
ebsites for Australia, Canada, Germany, Switzerland, and the UK
10,12,14,19,20], in a decree for France [22] and in the charter
f Advisory Committee on Immunization Practices (ACIP) for the
S [23]. NITAGs’ functions were not conﬁned solely to the terms
f reference. Additional missions were identiﬁed, as speciﬁed in
able 3, through ofﬁcial sources such as the German Standing Vac-
ination Committee’s (Ständigen Impfkommission; STIKO) Standard
perating Procedure [24], the Joint Committee on Vaccination and
mmunization’s (JCVI) code of Practice for the UK [25], and through
iterature review articles for France and Australia [26,27].
In sum, the main mission of all the selected NITAGs is to provide
dvice for NIP (Table 3). Other functions vary widely from one coun-
ry to another, from conducting risk-beneﬁt analysis for Germany
TIKO’s [24] and France’s Technical Vaccination Committee (Comité
echnique des vaccinations; CTV) [22] to drawing recommenda-
ions for vaccines’ research and development for Switzerland’s The
ederal Vaccination Commission (Commission fédérale pour les vac-
inations; CFV) [19] and Canada’s National Advisory Committee on
mmunization (NACI) [28] (Table 3).
.4. Parent organizations and reporting line
NITAGs’ parent organizations are national health agencies,
ouncils or ministries for most countries, such as the High Coun-
il for Public Health of France [13], the Superior Health Council of
elgium [11], National Authority for Public Health of Hungary (pri-
ary research), the Department of Health and Ageing of Australia
10], the Public Health Agency of Canada [12], the National Board
f Health and Welfare of Sweden [18], the Federal Ofﬁce of Public
ealth of Switzerland [19], the Health Council of the Netherlands
16], and the National Health System’s Inter-territorial Council of
pain [29]. The Robert Koch Institute (RKI) provides all administra-
ive support to the STIKO [14], and the ACIP hold its meetings at the
enters for Disease Control and Prevention (CDC) [21].
Even if parent organizations vary from one country to another,
ITAGs’ recommendations ultimately reached policy decision mak-
rs. Indeed, JVCI advises the Secretary of State for Health, Welsh
inisters but also the Scottish and Northern Irish ministers [20,25],
he Australian Technical Advisory Group on Immunization (ATAGI)
rovides advices to the Minister for Health and Ageing [10], the
ACI reports to the Chief Public Health Ofﬁcer of Canada [12], the
FV advises the Federal Department of Home Affairs and the Federal
fﬁce of Public Health [19], the ACIP reports to the Secretary and the
ssistant Secretary for Health and the CDC Director [23] and STIKO
ecommendations are forwarded to the Health authorities and the
fﬁce of the Federal Joint Committee after the RKI’s decision [14]. Ta
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Table  4
Composition of NITAGS and members’ proﬁle.
Members Core members’ Proﬁles
Core members* Stakeholders Composition Snapshot of 2011
Committee+
European countries
Belgium 29‡ 3‡ Members are afﬁliated to a Belgian University and are
selected based on their experience and knowledge in the
ﬁeld of vaccines
n/a
France 17 [22] 9 [22] Specialists in infectious disease; pediatricians;
microbiologists; specialists in epidemiology and public
health; general practitioners; immunologist;
geriatrician; gynecologist-obstetrician/midwife;
internist; workplace physician; health economist;
sociologist [22]
8 MDpˆ4 Public health
specialistspˆ3 Biologistspˆ1
Health economistpˆ1
sociologist [22]
Germany 12–18 [14] n/a¥ Experts from different scientiﬁc disciplines of science
and in the ﬁeld of public health as well as medical
professionals, who  have extensive, practical experience
on vaccination [14]
8 MDpˆ5 Public health
specialistspˆ4 Biologists
[14]
Hungary 12‡ 0‡ Members are OEK employees who are experts in
infectiology and virology
n/a
Italy 24‡ 0‡ n/a n/a
The  Netherlands 13‡ 3‡ Members have different backgrounds such as:
pediatricians, immunologists, epidemiologists,
Health-economists, microbiologist, public health
physicians, general practitioner, internal medicine,
virologists, occupational health physician, ethicist
n/a
Spain 19‡ 5‡ n/a n/a
Sweden¤ 0‡ 18‡ Employees from the National Board of Health and
Welfare, expert from outside the board as well as
relevant people from other public agencies
n/a
Switzerland 16 [31] 4‡ All Members are from the medical ﬁeld and have
expertise in all areas of immunization. Members are
chosen for their expertise and taking into account a
balanced gender distribution and regions [19]
7 MDpˆ7 Public health
specialistspˆ2 Biologists
[31]
UK# 18 [20] n/a Membership is determined on suitability for the role.
Members bring relevant knowledge, skills and
experience to the committee [25]
8 MDpˆ4 Public health
specialistspˆ2 Biologistspˆ1
Health economistpˆ2
Nursespˆ1 Ethicist [20]
Non-European countries
Australia 11 [10] n/a Technical experts, general practitioners and a consumer
[10]
6 MDpˆ2 Public health
specialistspˆ1 Biologistspˆ1
Nursepˆ1  Consumer
representativepˆ[10]
Canada 13 (in general 12)
[12]
17** [12] Recognized experts in the ﬁelds of pediatrics, infectious
diseases, immunology, medical microbiology, internal
medicine, nursing, pharmacy and public health [28]
n/a
US  14 [21] 34++ [30] Experts in infectious diseases, pediatrics, internal
medicine, family medicine, virology, immunology, public
health, preventive medicine, vaccine research and policy,
economics and cost-effectiveness, plus a consumer
representative [30]
12 MDpˆ1 Public Health
Expertpˆ1 Consumer
representative [21]
* Voting members except for Hungary and Spain as the Spanish committee decides by consensus [3], and voting is not applicable for the Hungarian committee as it is a
decision-support body (primary research).
+ Nearest year.
‡ Data retrieved from Immunization Advisory Committees (2008) [3].
¥ In Germany representatives of the RKI, the Ministry of Health, the Federal States, the national regulatory authority (Paul-Ehrlich-Institute), the Federal Centre for Health
Education, the Joint Federal Committee, the Ministry of Foreign Affairs, and the Federal Armed Forces participate in the meetings without voting right [14].
¤ The National Board of Health and Welfare in Sweden does not operate with a vaccine committee as such. ‘Vaccine committees’ are not ﬁxed group/committees, but
committees are founded on an ad-hoc basis (according to disease focus, e.g. HPV, hepatitis etc.).
§ As per primary research.
# The Committee consists of such number of members as the Secretary of State for Health and Welsh Ministers determine. Observers from the UK Govern-
ments/Administrations (i.e. ofﬁcials from the Devolved Administrations) attend JCVI meetings and receive committee papers. Scottish and Northern Ireland observers
may  as well attend.
** 10 liaison members and 7 ex ofﬁcio.
3
v
w
t
t++ 26 liaison members and 8 ex ofﬁcio.
.5. NITAGs’ proﬁle of members
Most committees were composed of core members, deﬁned as
oting members, except for Spain and Hungary, and stakeholders
hich can be either ex ofﬁcio or liaison members (Table 4). The
otal number of NITAGs’ members varied greatly from one coun-
ry to another and ranged from 48 in the US to 12 in Hungary. AllNITAGs, with the exception of Australia and Hungary, had more
than 15 members in 2011 and 6 NITAGs out of 13 had more than
20 members (Table 4).The number and function of members were clearly deﬁned
only for the ACIP and the CTV. Indeed, ACIP exact composition was
deﬁned in ofﬁcial sources [21], with the committee having to be
composed of 15 voting members, 8 ex ofﬁcio members(deﬁned
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s representing other federal agencies with responsibility for
mmunization programs)and 26 liaison members (deﬁned as
epresentatives of liaison organizations). For France, the CTV
ecree ﬁxed the number and proﬁles of voting members [22].
owever, NITAGs’ compositions and members’ proﬁles were not
s clearly deﬁned in the other NITAGs. Core members’ proﬁles
iffered from one NITAG to another and could even differ from
ne mandate to another for the same NITAG due to a lack of
equirements for members’ proﬁles (Table 4). For example, STIKO
ore members’ number could vary between 12 and 18, with
embers deﬁned roughly as experts from different disciplines
uch as science, public health, medical science with extensive and
ractical experience of vaccinations [14]. However, even though
ITAGs’ composition differed greatly, medical doctors represented
he highest proportion of member specialists in 2011, followed by
ublic health specialists, and biologists (Table 4).
Sub-committees, also called working groups, aiming to review
vailable data on speciﬁc topics on vaccine and develop back-
rounds for development of recommendations, were identiﬁed in
ll selected countries except Hungary, Italy, the Netherlands, Spain
nd Sweden [11,24–28,30,31]. Sub-committees could be composed
y committee members and experts outside the NITAGs’ members
nd may  or may  not be permanent [25,30].
.6. NITAGs’ appointment process
Committee members are appointed by representatives of Health
inistries or agencies for 6 NITAGs (Australia, Canada, France,
ermany, Sweden and the US) [14,22,23,27,28]. In the UK, while
he power to appoint JCVI members is held by Welsh Ministers
nd the Secretary of State for Health, the latter has delegated his
ppointment functions to the Appointments Commission which
akes appointments on merit, usually after advertising each
acancy and specifying the qualities required [25]. Committee
embers are appointed by the department of home affairs in
witzerland [19] and by the chairman of the Health Council in the
etherlands.
Duration of members’ appointment was 4 years in Australia,
anada, France, Switzerland, the Netherlands, the UK and the
S [19,22,23,25,27,28] and 3 years in Germany [14]. There is
o ﬁxed duration of appointment for committee members in
weden, and mandated duration was not speciﬁed for Hungary
primary research). Data was not available for Belgium, Spain and
taly.
Core members are remunerated in Australia, Belgium, the
etherlands and the US [21,23,32] but not in France, Germany,
weden, Switzerland, and the UK [14,24–26]. Committee members
eclare conﬂict of interest in the majority of the selected countries:
ustralia, Belgium, Canada, France, Germany, the Netherlands,
weden, Switzerland, the UK, and the US [13,14,19–21,27,28]. Usu-
lly, the declarations are available on NITAGs webpages [13,19–21].
onﬂict of interest declarations are not required in Hungary
primary research), and data were not available for Italy and
pain.
.7. Recommendation-making: Decision analysis framework and
eeting process
Germany and the US use a detailed and standardized methodol-
gy for reliable, robust and reproducible assessments: the Grades
f Recommendation, Assessment, Development and Evaluation
GRADE) [14,21,24,30]. Canada, Italy, Spain and Switzerland’s Com-
ittees do not use tools as robust and reliable as GRADE but list
learly their decision-making criteria [29,33–35] (Table 5). France,
weden and the UK state some of the decision-making criteria
ithout deﬁning a clear decision analysis framework [18,25,26] Ta
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Table  6
Access to information related to NITAG activities.
Meetings open to
public
Published meeting
agenda
Published meeting
minutes
Published NITAG
advices
Published evaluation
reports
Yes US [21] UK [20,25]; US [21] AU [10]; UK [20]; US
[21]
AU [27]; BE [11]; CA
[28]; CH [31]; DE [24];
ES [17]; FR [26]; HU*;
NL*; SE*; UK [25]; US
[21,30]
AU [27]; BE [11]; CA
[28]; CH [31]; DE [24];
ES [17]; FR [26]; HU*;
NL [16]; UK [25]; US
[30]
No BE*; CA [28]; CH [31];
DE [24]; FR [26]; HU*;
NL*; SE*; UK [25]
AU [10]; BE*; CA [12];
DE [24]; FR [26]; HU*;
NL*; SE*
BE*; CA [28]; CH [31];
DE [24]; FR [26]; HU*;
NL*; SE*
Not found IT; ES; AU CH; IT; ES; ES; IT IT SE; IT
AU: Australia, BE: Belgium, CA: Canada, CH: Switzerland, FR: France, DE: Germany; HU: Hungary, IT: Italy, NL: the Netherlands, ES: Spain, SE: Sweden, UK: the United
Kingdom, US: the United States.
* As per primary research.
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wTable 5). Decision-making criteria were not found for Australia,
elgium and Hungary, and ofﬁcial NITAGs’ time to advice after
egulatory approval was not retrieved for all selected countries.
Advices are publicly available in all selected countries except
taly, where only the national plan of immunization was  retrieved
11,24–28,30,31] (Table 6). Only Australia, the UK, and the US pub-
ished meeting minutes [10,20,21], and meetings were open to
ublic only in the US [21] (Table 6).
.8. Comments and outcomes of the expert panel
Experts validated the ﬁndings of the research and acknowledged
hat vaccines needed a country-speciﬁc and distinct decision-
aking paths compared to other drugs. The panel provided detailed
erspectives on Spain and Italy. Speciﬁcally, experts pinpointed
hat, public health decision-making is decentralized in the two
ountries. Thus, vaccine assessment and recommendation are
andled mainly at regional level, making it difﬁcult to retrieve
nformation at the national level.
Experts highlighted the fact that decision-making processes for
accines were not always as structured and transparent as pro-
esses for other medicines, thus leaving room for higher political
nﬂuence. The panel underlined the importance of vaccines from a
ublic health perspective and regretted the scarcity of public infor-
ation about NITAGs and their processes. Indeed experts’ broad
pinion is that NITAG appraisals should be better reported to the
eneral public and the overall information about vaccines should
e enhanced. There is a need to provide more information to the
ublic and health councils on reasons for no recommendation (e.g.
ack of data, lack of budget, etc.) in order not to jeopardize trust in
accines.
Finally, experts’ opinion was that NITAGs’ recommendations
hould not only be restricted to vaccine of the NIP, fully funded by
he public health system, but also concern other vaccines, thereby
llowing individuals’ access to vaccines with partial or full out-of-
ocket payment, as in Switzerland.
. Discussion
The aim of this project was to compare and analyze NITAG
odies and working processes of 13 developed countries. This com-
arison aimed to cover all aspects of NITAGs’ policies. However,
 number of limitations should be considered when interpreting
he results of the study due to the lack of data. Indeed, complete
nformation was not always retrieved despite using three sources,
nd few NITAG speciﬁc publications were available. Furthermore,
o direct contact could be established for Italy and Spain, for which
ith amount of available information via ofﬁcial sources andarticles was quite low, leaving a gap in retrieved data. And ﬁnally,
the study was limited to the formalized process, either published
in literature or websites, which, not being systematically updated,
might not reﬂect the actual NITAG’s functioning.
Over 80% of the information was retrieved for 9 out of 13 coun-
tries, allowing for a robust analysis of the data (Table 2). The level
of publicly available information varied highly from one country
to another. Data about NITAGs’ body and processes was clear and
readily available for a few countries, such as Germany, the UK  and
the US and scarce and incomplete for several other countries such
as Hungary, Spain and Italy (Table 2).
None of the selected NITAGs covered the recommended man-
date as deﬁned by Duclos et al. [6] (Table 3), and the terms of
reference did not cover all actual roles of NITAGs, suggesting that
terms of references needed to be updated and new functions of
NITAGs fully acknowledged.
Committee members’ number and proﬁles were not clearly
stated in most countries, with committees’ body varying between
countries and years. Only 6 NITAGs had between 10 and 16 core
members as recommended by Duclos et al. [6]. The number of core
members exceeded 16 in 6 countries, suggesting the need for a
very accurate and effective decision analysis framework to ensure
a good process with reliable and reproducible recommendations
(Table 4). And while Duclos et al. [6] recommended that members
be remunerated in order to avoid them giving low priority to their
NITAG roles, only 4 NITAGs remunerated their members.
Decision analysis frameworks were only available in 10 out
of the 13 selected countries (Table 5). These frameworks using
decision criteria are critical for a transparent, structured, repro-
ducible and reliable decision-making [8], as they help increase
trustworthiness in introducing new vaccines in the NIP, as well
as in promoting public conﬁdence [36]. Lack of standardization in
vaccine evaluation was identiﬁed as cause of heterogeneity and
inequity of immunization programs [34]. Nevertheless, the use of
efﬁcient decision-making tools, such as GRADE, has been devel-
oping and is expected to expand to more countries in the coming
years.
This study also illustrated the very restricted access to impor-
tant information such as agenda, meeting minutes and full reports.
With NITAGs recommendations being ultimately used by policy
decision makers for implementation and funding of NIPs, guidances
should be well-informed and transparent. Moreover, open data
and solid decision-making process are critical for NIP’s reliability
among the public and health care professionals. Indeed, while lack
of access to decision-making processes can have a negative impact
on the vaccination’s perceived value, understanding of vaccination
recommendations, implementation and funding processes, may
reduce time-to-access for new vaccines [37].
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Finally, although the speciﬁc characteristics of vaccines need to
e acknowledged in determining the evaluation process, the deci-
ion processes would beneﬁt from studying the progress of HTA
gencies in general over the last 10 years, especially relating to the
nalytical decision framework, the time to issuing advice, and the
ractice of publishing appraisals.
. Conclusion
This study supports previous ﬁndings about the heterogeneity
f NITAGs processes, potentially explain the disparity in access to
accinations and immunization programs across Europe [37,38].
learly deﬁned terms of reference that reﬂect the roles and mis-
ions, structured decision analysis framework for the evaluation of
he vaccines, together with initiatives such as the VENICE II project
7] that provide access to information and reports, are therefore
eeded to support the development of best practices among the
ITAGs and enhance reliability of NIP.
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Appendix A. Appendix 1 Research strategy
OVID Medline
#1 ((((immuiii* or vacciti* or innoculat*) in ti,ab) or ((explode
“Immunization-”/all
SUBHEADINGS in MIME,MJME,PT) or (explode “Vaccines-”/all
SUBHEADINGS in MIME,MJME,PT) or (explode
“Immunization-Programs”/all SUBHEADINGS in MIME,MJME,PT)))
#2  ((((mak* or responsib* or authori*) near3 (policy or policies or
decision*)) in ti,ab) or ((explode “Decision-Making”/all SUBHEADINGS in
MIME,MJME,PT) or (“Policy-Making”/WITHOUT SUBHEADINGS in
MIME,MJME,PT))))
#1  and #2
Global Health
1) TI mak* N3 polic* or TI responsib* \3 polic* or AB mak* N3 polic* or AB
responsib* N3 polic*
2) TI mak* N3 decision orTI responsib* N3 decision or AB mak* N3 decision
or AB responsib* N3 decision
3) TI immuni* or AB iinmuni* or TI vaccin* or AB vaccin* or TI innoculat*
and AB innoculat*
4) TI authori* N3 polic* or TI authori* N3 decision or AB authori* N3
decision or AB authori* \3 polic*
5)  decision making or policy making
6) 1 or 2 or 4 or 5
7)  6 & 3
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